button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1)

versus placebo
avelumab alone vs. placebo 1 1.0better0.35.094 %1.0better0.35.092 %-

mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 1 1.0better0.35.098 %1.0better0.35.0100 %-
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 1 1.0better0.35.0100 %1.0better0.35.082 %-

mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive

versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU 2 1.0better0.35.099 %1.0better0.35.094 %-
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU 2 1.0better0.35.0100 %1.0better0.35.097 %-

mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population

versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 1.0better0.35.089 %1.0better0.35.058 %-
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 1.0better0.35.065 %1.0better0.35.081 %-
nivolumab alone vs. Standard of Care (SoC) 1 1.0better0.35.099 %1.0better0.35.083 %-
pembrolizumab alone vs. Standard of Care (SoC) 1 1.0better0.35.098 %1.0better0.35.066 %-

mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative

versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone 1 1.0better0.35.052 %1.0better0.35.077 %-
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab 1 1.0better0.35.097 %1.0better0.35.097 %-

mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 1.0better0.35.099 %1.0better0.35.054 %-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons